MELK/MPK38 in cancer: from mechanistic aspects to therapeutic strategies
| Autor: | Lavanya Ponnusamy, Sathan Raj Natarajan, Ravi Manoharan, Karthik Thangaraj |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cell signaling Antineoplastic Agents Protein Serine-Threonine Kinases Biology medicine.disease_cause Maternal embryonic leucine zipper kinase 03 medical and health sciences 0302 clinical medicine Neoplasms Drug Discovery medicine Animals Humans Protein Kinase Inhibitors Pharmacology Kinase Cell growth Cancer medicine.disease 030104 developmental biology Apoptosis 030220 oncology & carcinogenesis Cancer research Phosphorylation Carcinogenesis |
| Zdroj: | Drug Discovery Today. 25:2161-2173 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2020.09.029 |
| Popis: | Maternal embryonic leucine zipper kinase (MELK)/Murine protein serine-threonine kinase 38 (MPK38) is a member of the AMP-related serine-threonine kinase family, which has been reported to be involved in the regulation of many cellular events, including cell proliferation, apoptosis, and metabolism, partly by phosphorylation and regulation of several signaling molecules. The abnormal expression of MELK has been associated with tumorigenesis and malignant progression in various types of cancer. Currently, several small-molecule inhibitors of MELK are under investigation although only OTS167 has entered clinical trials. In this review, we elaborate on the relative contributions of MELK pathways in the physiological process, their oncogenic role in carcinogenesis, and targeted agents under development for the treatment of cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect